DarioHealth Corp.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Erez Raphael
- Full Time Employees
- 163
- Sector
- Healthcare
- Industry
- Medical - Specialties
- Address
- 322 W. 57th Street New York City NY United States of America 10019
- IPO Date
- Mar 14, 2016
- CIK
- 0001533998
- Website
- dariohealth.com
- Similar Companies
- Business
- DarioHealth Corp. (NASDAQ: DRIO) operates as a global digital therapeutics company that delivers personalized, evidence-based interventions through its user-centric platform, integrating software, connected devices, AI-driven data analytics, and one-on-one coaching to manage chronic conditions including diabetes, hypertension, weight management, musculoskeletal pain such as posture, injury, and pain issues, and behavioral health conditions like anxiety, depression, and stress; core offerings encompass the Dario mobile app with real-time monitoring and hypo-alerts, DarioEngage population health management platform, Dario Loop AI journey engine, Dario Tools smartphone-integrated devices, digital coaching via chat with educational content, and expanded GLP-1 solutions with prescribing capabilities, targeting health plans, self-insured employers, providers, pharmaceutical companies, and direct-to-consumer markets primarily through B2B2C channels in the United States, Canada, the European Union, Australia, and New Zealand. Founded in 2011 as LabStyle Innovations Corp. in Caesarea, Israel, with principal executive offices in New York and ongoing R&D in Israel, the company focuses on disrupting traditional episodic healthcare with continuous, customized care to drive sustainable behavior change and clinical outcomes like HbA1c reductions and risk diminutions. Recent developments include the strategic acquisition of Twill in early 2024 to broaden multi-condition offerings and achieve immediate scale with top national health plans and Fortune 100 employers, a $25.6 million private placement in 2025 to fund growth toward operational cash flow positivity by year-end, new partnerships such as with BCBS launched in January 2025 and MediOrbis for GLP-1 expansions, signing of four new employer contracts and 79 new accounts exceeding 2025 targets as of December 2025, and contracts covering over 2.8 million eligible lives with demonstrated revenue growth including 111% year-over-year in Q3 2024.
Company News
Dario Wins Contract with One of New Jersey's Largest Health Plans Representing 1.5 Million Covered Lives
DarioHealth (NASDAQ:DRIO) Share Price Passes Below Two Hundred Day Moving Average – Here’s What Happened
Pro Medicus (OTCMKTS:PMCUF) versus DarioHealth (NASDAQ:DRIO) Head to Head Survey
Contrasting DarioHealth (NASDAQ:DRIO) and Phreesia (NYSE:PHR)
DarioHealth Corp. (DRIO) Q2 2026 Earnings Call Transcript
DarioHealth Q2 Earnings Call Highlights
DarioHealth Corp. (DRIO) Reports Q2 Loss, Lags Revenue Estimates
DarioHealth Reports Second Quarter 2026 Financial Results
Dario Expands Provider-Backed Cardiometabolic Platform with New Women's Health and Sleep Solutions Aligning with Client Demand
DarioHealth to Report Second Quarter 2026 Results on Tuesday, August 11, 2026
Dario Launches Integrated GLP-1 Program, Combining Its Digital Chronic Care Platform with Provider-Backed Clinical Care in a Single End-to-End Experience
DarioHealth (DRIO) Moves 12.9% Higher: Will This Strength Last?
Dario Announces Pricing of a $23.5 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
Financial Analysis: Echo Therapeutics (OTCMKTS:ECTE) vs. DarioHealth (NASDAQ:DRIO)
Fortune 50 Employer Awards Dario Contract to Deliver AI-Powered Cardiometabolic Care Platform
Dario Expects Proprietary AI Engine DarioIQ™ to Increase Recurring Revenue from Existing Customers by 10-15%
Dario Signs New Agreement with a Major Health Insurer in Arizona Representing Hundreds of Thousands of Lives Through Amwell Partnership
Top National Health Plan Extends Agreement for Mental Health and Expands Dario Partnership into Cardiometabolic Care, Demonstrating Successful Multi-Condition Growth Strategy
Top National Health Plan Extends Agreement for Mental Health and Expands Dario Partnership into Cardiometabolic Care, Demonstrating Successful Multi-Condition Growth Strategy
Dario Appoints Former Humana Chief Compliance Officer Sean O'Reilly to Advisory Board to Support Strategic Growth and Healthcare Partnerships